$VIVO (Meridian Bioscience, Inc.)

$VIVO {{ '2016-10-19T17:00:35+0000' | timeago}} • Announcement

$VIVO expects FY16 revenue of about $196MM, an increase of 1% from prior year, and EPS of $0.75-0.76. The EPS forecast includes costs related to acquisition activity and costs associated with the reorganization of Diagnostics sales and marketing leadership. The preliminary results reflect 4Q revenues of about $47MM.

$TMO {{ '2017-07-26T14:06:23+0000' | timeago}} • Webcast

$TMO said the upward revision of 2017 financial outlook mainly reflected the less adverse foreign exchange environment. The company continues to expect 4% organic revenue growth for the year. Excluding the effect of foreign exchange headwinds, adjusted EPS is seen growing 12-14%. Adjusted operating margin is forecast to grow 50-60 basis points YoY.

$TMO {{ '2017-07-26T13:46:17+0000' | timeago}} • Webcast

Scientific equipment maker $TMO said pharma and biotec continued to be its strongest end markets in 2Q17, with mid-single digits growth. The company's growth strategy remains centered on launching innovative products and leveraging the scale in Asia Pacific and emerging markets. In 2Q17, Thermo Fisher completed $250MM of share buybacks.

$TMO {{ '2017-07-26T12:48:19+0000' | timeago}} • Infographic

$TMO Thermo Fisher Scientific, Inc. Earnings AlphaGraphic: Q2 2017 highlights

$TMO {{ '2017-07-26T10:56:26+0000' | timeago}} • Announcement

Among $TMO’s business segments, Life Sciences Solutions posted a 3% YoY growth in 2Q17 revenues. Analytical Instruments segment revenues surged 47%, reflecting the acquisition of FEI Company last year. Revenues of the Specialty Diagnostics segment and Laboratory Products & Services segment advanced 1% and 4%, respectively, compared to 2Q16.

$TMO {{ '2017-07-26T10:42:34+0000' | timeago}} • Announcement

$TMO revised up its fiscal 2017 revenue guidance to the range of $19.71-$19.89Bil from the previous outlook of $19.51-$19.71Bil, indicating an 8-9% annual growth. The guidance of adjusted EPS has been raised to $9.15-$9.28 per share from the earlier forecast of $9.12-$9.28 per share, which will result in an 11-12% YoY increase.

$TMO {{ '2017-07-26T10:33:50+0000' | timeago}} • Announcement

Medical instruments maker $TMO reported strong results for 2Q17, continuing the recent trend. Earnings of the company, which is currently on an acquisition spree, jumped 20% YoY to $1.56 per share. Adjusted earnings, excluding special items, grew 13% to $2.3 per share. The bottom line growth was driven by a 10% increase in revenues to $4.99Bil.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$JNJ {{ '2017-07-24T17:21:48+0000' | timeago}} • Announcement

$JNJ said preliminary data from a phase 1/2a clinical trial on an investigational HIV-1 vaccine regimen showed positive results in a sample of 393 healthy volunteers. If the vaccine clears the phase 3 trials, its launch can be expected within a decade. There are currently around 37MM AIDS patients around the world.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$TMO {{ '2017-07-19T12:44:47+0000' | timeago}} • Announcement

$TMO priced an offering of EUR2.6Bil of senior notes. The issuance of the notes is expected to close on or about July 24, 2017. $TMO plans to use all of net proceeds to fund a portion of consideration payable for its acquisition of Patheon, including the repayment of debt of Patheon to be assumed by $TMO, which is estimated to be about $7.2Bil.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

Recent Transcripts

TMO (Thermo Fisher Scientific, Inc.)
Wednesday, July 26 2017 - 12:30pm
TRIB (Trinity Biotech plc)
Thursday, July 20 2017 - 3:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
NEOG (Neogen Corp.)
Tuesday, July 18 2017 - 3:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
BIO.B (Bio-Rad Laboratories, Inc.)
Thursday, May 4 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, May 2 2017 - 8:30pm
MYGN (Myriad Genetics, Inc.)
Tuesday, May 2 2017 - 8:30pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
TRIB (Trinity Biotech plc)
Thursday, April 27 2017 - 3:00pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, April 26 2017 - 12:30pm

AlphaGraphics you may like